• 參考資料PM-COR-22-112808

    1. Dymista® (azelastine hydrochloride/fluticasone propionate) Prescribing Information. Viatris Healthcare Hong Kong: Version August 2020.
    2. Bousquet J, Meltzer E, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732.
    3. Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369-377.
    4. Price D, Bousquet J, Bachert C, et al. A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex. Clin Transl Allergy. 2013;3(Suppl 2):P45.
    5. Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495-503.
    6. Bousquet J, Schunemann H, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.
    7. Hellings PW, Scadding G, Bachert C, et al. EUFOREA treatment algorithm for allergic rhinitis. Rhinology. 2020;58(6):618-622.